Numerous studies have reported overexpression of EGFR in 27–100% of solid tumors, including NSCLC, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), gastric-gastroesophageal junction cancer, urothelial cancer, clear cell renal cell carcinoma, hepatocellular carcinoma, glioblastoma, pancreatic cancer, and breast cancer, among others (4, 6, 10, 15). Here, EGFR is linked to glioblastoma.